News

Measures of IPF Therapy Effectiveness Should Include Patients’ Views of Success, Researchers Argue

Clinical trials of idiopathic pulmonary fibrosis (IPF) therapies should include measures that reflect patients’ views of the success of treatments, Columbia University Medical Center researchers contend. In particular, the trials should add reduction in respiratory-related hospitalizations to their measurement tool kit, the team said. Patients’ views of treatment success could influence…

European Commission Approves New Esbriet Tablet for IPF Treatment

The European Commission (EC) recently approved a new formulation of Esbriet (pirfenidone) tablets for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). According to Roche, Esbriet’s developer, the new tablet formulation will reduce the number of pills patients need to take throughout the day, offering patients an easier…

Supplemental Oxygen During Exercise Can Benefit Pulmonary Fibrosis Patients, Study Finds

Supplemental oxygen during exercise can improve pulmonary fibrosis patients’ breathing and workout capabilities, according to a report in the journal Respirology. A key feature of idiopathic pulmonary fibrosis (IPF) is higher levels of damaging oxygen oxidants, or substances that oxidize other substances. These compounds trigger tissue scarring known as…

Australian IPF Registry Identifies Characteristics, Predictors of Mortality Among Idiopathic Pulmonary Fibrosis Patients

Australia’s national registry of patients with idiopathic pulmonary fibrosis (IPF) includes patients of diverse ages, disease severity and co-morbidities, and shows that baseline lung function and GAP (gender, age, physiology) stage are important prognostic markers for mortality. The study, “Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the…